Mineralys Therapeutics Chief Medical Officer David Malcom Rodman sold 20,407 shares for approximately $557,000 on July 13 and 15, 2026, according to an SEC filing. The transaction was executed under a Rule 10b5-1 trading plan adopted on October 6, 2025, and involved the simultaneous exercise of 20,407 stock options at strike prices between $1.08 and $14.25 and an immediate open-market sale at a weighted average price of $27.28 per share. Following the sale, Rodman directly holds 51,384 shares, while retaining vested and unvested stock options. The sale occurred as Mineralys shares had returned 87% over the prior 12 months, with the company advancing its lead candidate lorundrostat ahead of a December 22 FDA decision date.
Mineralys Therapeutics, Inc. Common StockCMO sold $557k in shares under a 10b5-1 plan, which may signal insider sentiment despite the plan's pre-set nature.